NEUMORA THERAPEUTICS, INC. Proceeds from Common Stock Issued
NEUMORA THERAPEUTICS, INC. (NMRA) reported Proceeds from Common Stock Issued of $810.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-03-03
- NEUMORA THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00.
- NEUMORA THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2023 was $810.00K.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $810.00K 10-K · filed 2025-03-03 | |
| 2023-09-30 | $810.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |